Why We Invested · World Fund
Investment thesis
World Fund's investment thesis rests on ENOUGH's ability to rapidly scale an alternative protein solution that overcomes current market limitations.
Our investment thesis is based on ENOUGH’s ability to contribute to solving these challenges by rapidly scaling an alternative protein solution that is overcoming current market limitations.
Why the firm invested
World Fund co-led ENOUGH's Series C round alongside CPT Capital to fund capacity expansion at ENOUGH's Sas van Gent factory.
We are excited to be co-leading ENOUGH’s Series C round alongside CPT Capital - a renowned food tech investor. The new funding will be used to scale up capacity at the company’s factory in the Sas van Gent to serve growing customer demand.
Product
ENOUGH creates ABUNDA mycoprotein by fermenting fungi using renewable feedstocks, providing high protein and fibre with a meat-like texture and neutral flavour.
ABUNDA is created by fermenting fungi using renewable feedstocks. It is naturally high in both protein and fibre and offers a meat-like texture with a neutral flavour, allowing for clean labels.
Traction
Founded in 2015, ENOUGH has spent years co-developing alternative protein products with a global base of B2B food customers.
Founded in 2015, ENOUGH has spent the last couple of years co-developing alternative protein products with a global B2B food customer base.
ENOUGH will be able to produce 60,000 tonnes of ABUNDA annually at its Sas van Gent facility and targets over 1 million tonnes globally by 2032.
At its existing Sas van Gent site ENOUGH will be able to produce 60,000 tonnes of ABUNDA annually. By 2032, the company aims to grow over one million tonnes of ABUNDA globally
Business model
ENOUGH supplies its ABUNDA mycoprotein to B2B large-scale customers to produce sustainable non-animal protein products.
ENOUGH is a leading British/Dutch food technology company dedicated to creating sustainable non-animal protein - the ABUNDA® mycoprotein for B2B large-scale customers.
Competition
ENOUGH can offer ABUNDA at price points competitive with both existing plant-based alternatives and real animal meat.
ENOUGH is in the advantageous position to offer ABUNDA at pricing points that are competitive not only to existing plant-based but also to real-animal meat offerings.
What founders can learn
- What actually moved the decision: World Fund wrote that World Fund co-led ENOUGH's Series C round alongside CPT Capital to fund capacity expansion at ENOUGH's Sas van Gent factory.
- The traction evidence that carried weight: World Fund wrote that Founded in 2015, ENOUGH has spent years co-developing alternative protein products with a global base of B2B food customers.
- How the model was assessed: World Fund wrote that ENOUGH supplies its ABUNDA mycoprotein to B2B large-scale customers to produce sustainable non-animal protein products.
Source and provenance
Why We Invested published by World Fund on worldfund.vc (first-party source). Read the original
